• Nenhum resultado encontrado

[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.35 número5

Has 10000 "Rev. Bras. Hematol. Hemoter. vol.35 número5" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.35 número5".

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... At the start of this millennium, the studies and results of cell therapy in degenerative and chronic diseases, the emergence of the concepts of cellular plasticity (7-9) , transdiffere[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... The results showed that autologous cell therapy with a pool of BMMC in patients with advanced stage COPD is a safe procedure without signiicant adverse effects.. Furthermore, the [r] ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... As clinical evaluations may not be suficient to adequately characterize the morbidity associated with hemophilia (7,8) , the present study aimed to measure HRQoL in adults with hemophi[r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Dysplastic changes in all hematopoietic lineages and peripheral cytopenias have also been described in SLE patients; however, they seem to be reversible with remission of the diseas[r] ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... In this work, FISH analysis using the ETV6/RUNX1 probe allowed the identiication of a rare chromosome abnormality with important prognostic impact, the iAMP21. Although iAMP21 has Fig[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... This is the irst report of aplastic anemia concurrent with systemic lupus erythematosus and acquired immunodeiciency syndrome, providing additional evidence that immune dysfunction is [r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Data about renal function of adults with sickle cell disease have been reported, but data on children is scarce, especially when comparing heterozygotic and homozygotic patients.. Objec[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... chemotherapy program without TBI using melphalan, cyclophosphamide and etoposide followed by consolidation-rescue with autologous hematopoietic progenitor stem cell transplantation (AH[r] ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Positive MRD on Day 28-35 was associated with a lower probability of LFS, but not signiicantly, in univariate analysis (p-value = 0.19; Figure 1B). When the prognostic impact of minimal residual disease at Day ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... In the current study, all HS patients presented with a severe form of HS and portal hypertension, 38 (69%) had advanced and very advanced liver ibrosis (pattern E+F) and 34 (61.8%) pat[r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... to 35-year ...from 35 to 44 years the missing component accounted for ...to 35-year and 36- to 59-year categories, whereas in the national epidemiological survey, adults were grouped in the age range ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... The goal of this study was to evaluate the quality of life of sickle cell disease patients (hemoglobin SS and SC) and their sociodemographic and clinical characteristics.. Methods: Dat[r] ... See full document

7

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Comment on: Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years.. Sergio Paulo Bydlowski.[r] ... See full document

1

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation.. Morris Kle[r] ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... 7. Aquino RT, Chiefi PP, Catunda SM, Araújo MF, Ribeiro MC, Taddeo EF, et al. Hepatitis B and C virus markers among patients with hepatosplenic mansoni schistosomiasis. Rev Inst Med Trop Sao Paulo. ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Maybe the frequency of the hemoglobin C gene is higher in Minas Gerais, but maybe the ‘climate’ in the Belo Horizonte clinic is more welcoming and Hb SC patients whose quality of life [r] ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... established based on information from population surveys. A cross-sectional study conducted in Brazil showed that the proportion of caries-free individuals decreases as a function of age, and, at 5 years of age, ... See full document

1

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... Most of our QoL questionnaires consist of a number of questions answered on an ordinal categorical scale, however researchers often treat each question as yielding a continuous number. For example, the Canadian ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.35 número5

Rev. Bras. Hematol. Hemoter. vol.35 número5

... A cohort study involving 1056 patients with a median age of 20 years showed that after 40 years of follow up 12% developed renal failure at a median age of 37 years (1-3).. After the i[r] ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.35 número6

Rev. Bras. Hematol. Hemoter. vol.35 número6

... 19. Ferreira CM, Ferreira WA, Motta CL, Vasquez FG, Pinto AF. Reatividade do teste VDRL em bolsas de sangue da Fundação de Hematologia e Hemoterapia do Amazonas- HEMOAM, os custos decorrentes do descarte e estimativa de ... See full document

5

Show all 10000 documents...